Literature DB >> 7468159

Respiratory disease and nasal immunoglobulin concentrations in phenytoin-treated epileptic patients.

N E Gilhus, J A Aarli.   

Abstract

Symptoms of respiratory tract disease were recorded for half a year in 32 epileptic patients receiving phenytoin, and in 25 controls. There were 16 patients with normal IgA concentration in serum and nasal secretion, and 16 with a reduced concentration of IgA either in serum or in nasal secretion, or in both. Both groups of patients had significantly more frequent respiratory symptoms than did the controls (P less than 0.01). There was no difference when the patient group with decreased IgA concentrations was compared to that with normal IgA levels. All the four patients with IgA deficiency both in serum and nasal secretion had, however, more frequent symptoms than any of the controls. There was no difference regarding respiratory tract disease in patients taking phenytoin only, compared to those combining phenytoin and other anticonvulsants. IgG and IgM levels in nasal secretion showed no direct relationship to the frequency of respiratory symptoms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7468159     DOI: 10.1111/j.1600-0404.1981.tb00746.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  Immunoglobulins in epilepsy.

Authors:  J A Aarli
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Increased bacterial antibody titres and IgA deficiency in epileptic patients.

Authors:  M Iivanainen; J Syrjänen; O Waltimo; V V Valtonen; N E Gilhus
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-14

3.  IgG subclasses in epileptic patients treated with phenytoin.

Authors:  N E Gilhus; T Lea
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

4.  The IgA immune system in epileptics on anticonvulsant therapy.

Authors:  O Meissner; P H Joubert; H F Joubert; C A van der Merwe
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

6.  IgA in epileptics receiving anticonvulsant therapy.

Authors:  O Meissner; H F Joubert; P H Joubert; C H van der Meyden; W Studzinski
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  The reversibility of phenytoin-induced IgA deficiency.

Authors:  N E Gilhus; J A Aarli
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.